SWOT Analysis of Indian Pharma Industry

Weaknesses

1. Very low penetration in India. To put things in to perspective, India accounts for almost 16% of the world population while the total size of industry is Just 1% of the global pharmacy industry.
2. Due to very low barriers to entry, Indian pharmacy industry is highly fragmented with about 300 large manufacturing units and about 18,000 small units spread across the country. This makes Indian pharmacy market increasingly competitive.

Opportunities

1. The migration into a product patent based regime is likely to transform industry fortunes in the long term. The new patent product regime will bring with it new innovative drugs.
2. Large number of drugs going off-patent in Europe and in the US between 2012 to 201 5 offers a big opportunity for the Indian companies to capture this market.
3. Opening up of health insurance sector and the expected growth in per capita income are key growth drivers from a long-term perspective. This leads to the expansion of healthcare industry of which pharmacy industry is an integral part.
4. Being the lowest cost producer combined with FDA approved plants, Indian companies can become a global outsourcing hub for pharmaceutical products.

There are certain concerns over the patent regime regarding its current structure. It might be possible that the new government may change certain provisions of the patent act formulated by the preceding government. Threats from other low cost countries like China and Israel exist. However, on the quality front, India is better placed relative to China. So, differentiation in the contract

The short-term threat for the pharmacy industry is the uncertainty regarding the implementation of VAT. Though this is likely to have a negative impact in the shorter, the implications over the long-term are positive for the industry Other

Important News about Pharmacy Industry: Third Largest in the world in terms of volume & 13th largest in terms of value Total Market Size: RSI. 1233 ban Domestic Consumption: RSI. 600 ban & Exports: RSI. 633 ban Compounded Annual Growth Rate of the industry in past 5 years: 12. 5% Expected to grow at 15. 1% dung 2013-2017

Main Drivers for higher R & D costs in Indian Companies are:

1. increased pace of product filings in US and Europe,
2. focus on complex generics, some of which require clinical trials to demonstrate basic safety and efficacy and
3. investments in developing bookmobiles for emerging markets and eventually for plopped markets.

SWOT Analysis of Dry Redder

1. Company launched Peg-agreeable, an inexpensive variety of epigrammatic, used to fight infection in chemotherapy where company has sold some 1. 5 million units of it.
2. Diaphragm/Crotches acquisition provided proprietary choral and biostatistics technology
3. The acquisition of Beta pharmacy helped to introduce an array of generic products and show its presence in the European markets. Strength
4. Has a strong workforce of over 1 5,000 employees
5. Discovery of drugs is a highly unpredictable business

Strength

1. Wide global footprint as it is present in over 70 countries
2. High dependence on global formulation business with 84% revenue coming from US market
3. Forecasting done on technological level is less
4. It operates in low growth segments such CANS, respiratory diseases
5. Alliances health awareness
6. Emerging technological trends in drug delivery

Opportunity

• Increasing prevalence of TAB in developing countries
• Rigid opposition both from locals and global company
• Soaring cost of discovering novel products

USPS

• Commitment to make medicines affordable and accessible particularly to cancer patients
• Capital has developed good positive image by providing support to cancer patients by issuing drugs at low cost
• Imminent commencement of the Fixed-Dose combination for treatment of uncomplicated P. Follicular malaria to tackle the 200+ million cases of malaria globally
• Initiation of ‘No Touch Breast Scan’ a step forward in the screening technology in India.
• A foremost player in anti-infective and anti-asthmatic formulations.

About Ssun pharmacy

Managing Director -Deli S Shanghai Sun Pharmaceutical Industries Ltd is an international specialty pharmacy company. The company manufactures and markets pharmaceutical formulations as branded generics, as well as generics in India, the United States and several other markets across the world. The company’s business is divided into four segments: Indian Branded Generics, US Generics, International Branded Generics (ROW) and Active Pharmaceutical Ingredients (API). Their brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, gastroenteritis, adaptability and expiratory.

They make specialty Apish, including peptides, steroids, hormones and anticancer. Apish and Dosage forms are made at 20 plants across India, Israel, the United States, Canada, Hungary, Brazil, Mexico and Bangladesh. Sun Pharmaceutical Industries Ltd was incorporated in the year 1983. The company began operations in Kola with Just 5 products to treat psychiatry ailments. They set up a compact manufacturing facility for tablets/capsules at API. Sales were initially limited to two states in Eastern India. In the year 1986, the company set up an administrative office in Iambi.

They extended the customer coverage to select cities in Western India. In the year 1987, they rolled out their marketing operations nation-wide. Sun Pharmacy Industries Parent Company Category Pharmaceutical Sector Healthcare Tagging/ Slogan USPS Sun pharmacy fifth largest & most profitable company in India STEP Segment Cardiology, psychiatry, neurology, gastroenteritis, topology Target Group Healthcare professionals, pharmacists They are international specialty pharmacy company with strong Positioning presence in Indian & US generics market

In the year 2007, the company De-merged the innovative research and business into a new company, SPARS Ltd. SPARS Ltd was listed on the stock exchanges in India, the first pure research company to be so listed. In May 2007, the company along with their subsidiaries, signed definitive agreements to acquire Taro Pharmaceutical Industries Ltd. , (TAROT, Pink Sheets), a multinational generic manufacturer with established subsidiaries, manufacturing and products across the U. S. , Israel, Canada for $454 mill.

In November 2008, the company along with their subsidiaries acquired 100% ownership of Chatted Chemicals, Inc. , a narcotic raw material importer and manufacturer of controlled substances with an approved API facility in Tennessee. This offers vertical integration for our controlled substance dosage form business in he US. In September 2010, the company acquired Taro Pharmaceuticals. This acquisition doubled the size of their US business and brought them a range of generics including a strong line of dermatological.